Trial Profile
An open-label randomized controlled trial trial to investigate efficacy of ertapenem compared with group 2 carbapenems in extended-spectrum beta-lactamase-producing Gram-negative bacterial infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary) ; Carbapenems
- Indications Gram-negative infections
- Focus Therapeutic Use
- 16 May 2016 New trial record
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases